Charlottesville, VA-Use of molecular analysis for the uroplakin II (UPII) gene may potentially be a more sensitive method than conventional histopathology for identifying lymph node metastasis in patients with urothelial bladder cancer, according to a joint University of Virginia/University of Western Ontario study appearing in Clinical Cancer Research (2001; 7:1516-22).
Dosing commences in phase 1/2 trial of AB-2100 in ccRCC
May 15th 2024The dose escalation/dose expansion study is evaluating the safety and efficacy of AB-2100 in patients with ccRCC who either came back or did not improve following prior treatment with a checkpoint inhibitor and a VEGF inhibitor.